
Machine learning: Developing next generation antibody therapeutics
Ben Holland, CTO and Co-Founder of Antiverse, discusses how artificial intelligence and machine learning are benefitting antibody discovery and design. Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics. This remarkable progress in antibody modalities for… Read More















